Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737475 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
NCT02737475 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 166 participants.
The verdict
NCT02737475, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG BMS-986178
- BIOLOGICAL Tetanus vaccine
- BIOLOGICAL DPV-001 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2016-06-17 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02737475
The ClinicalTrials.gov registry entry for NCT02737475 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02737475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02737475 about?
NCT02737475 is a clinical study titled "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread". The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
What is the current status of trial NCT02737475?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2016-06-17. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT02737475?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), BMS-986178 (DRUG), Tetanus vaccine (BIOLOGICAL), DPV-001 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02737475?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.